Skip to content
A8836Assembly2023-2024 SessionSame asS8587

Track Rising Drug Costs

Official title

“Requires the commissioner of health to include in annual reports information regarding the cost and increase in cost of certain prescription drugs”

Sponsor Sam BergerAD-27Affects Health
Status
In Assembly Committee
Health
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill requires the New York health commissioner to annually report on prescription drugs with significant cost increases and their contributing factors.

Why it matters

  1. Increases transparency around drug price hikes. By requiring annual public reporting of the top ten prescription drugs with the largest recent price increases (both in wholesale cost and net cost to the state), the bill helps patients, providers, and policymakers to see which drugs are getting more expensive and by how much.

  2. Holds drug manufacturers accountable. Manufacturers of drugs on these lists must submit detailed reports explaining the reasons for significant price increases—including costs for manufacturing, R&D, marketing, and patient assistance programs—along with how much each factor contributed to the price hike and the company’s total revenue and profit. This could put public pressure on companies to justify their pricing strategies.

  3. Provides data for potential policy action. By breaking down which drugs drive the most state spending and documenting the reasons for price surges, the reports could inform future legislative or regulatory efforts to control state healthcare costs, negotiate better prices, or consider other interventions to address drug affordability.

  4. May impact future pricing behavior. The prospect of increased scrutiny and required justification for large price increases could deter manufacturers from imposing steep price hikes, especially if they cannot credibly justify them in their required reports.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Track Rising Drug Costs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Sam Berger

Assembly Member · Assembly District 27

No co-sponsors yet.

History

  1. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S8587Senate

Track Rising Drug Costs

In Senate Committee · Health · Sponsor Jessica Scarcella-Spanton

Impact 5 · Moderate0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8836

IN ASSEMBLY

January 18, 2024

Introduced by M. of A. BERGER -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to requiring the commissioner of health to include in annual reports information regarding the cost and increase in cost of certain prescription drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 1 of section 277 of the public health law, as amended by section 18 of part A of chapter 56 of the laws of 2013, is amended to read as follows:

1. The commissioner, in consultation with the drug utilization review board, shall undertake periodic reviews, at least annually, of the preferred drug program which shall include consideration of:

(a) the volume of prior authorizations being handled, including data on the number and characteristics of prior authorization requests for particular prescription drugs;

(b) the quality of the program's responsiveness, including the quality of the administrator's responsiveness;

(c) complaints received from patients and providers;

(d) (i) a list of the ten prescription drugs on which the state expends the most money and for which the wholesale acquisition cost has increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year. The commissioner shall: include the percentage of the wholesale acquisition cost increase for each drug on the list; rank the drugs on the list from those with the largest increase in wholesale acquisition cost to those with the smallest increase; indicate whether each drug was included on the list based on its cost increase over the past five years or during the previous calendar year, or both; and provide the state's total expenditure for each drug on the list during the most recent calendar year; and

(ii) a list of the ten prescription drugs on which the state expends the most money and for which the cost to the state, net of rebates and other price concessions, has increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD06654-01-3

year. The commissioner shall rank the drugs on the list from those with the greatest increase in net cost to those with the smallest increase and indicate whether each drug was included on the list based on its cost increase over the past five years or during the previous calendar year, or both; and

(iii) a manufacturer of a prescription drug that appears on a list as described in subparagraph (i) or (ii) of this paragraph shall submit to the commissioner a report that explains: (A) all material factors that have contributed to the wholesale acquisition cost increase for such drug including but not limited to materials and manufacturing costs, spending on research and development costs, spending on marketing and advertising, and spending on patient assistance programs; (B) the percentage of the total wholesale acquisition cost increase attributable to each factor; (C) an explanation of the role of each factor in contributing to the wholesale acquisition cost increase; (D) the total revenue and the net profit of the manufacturer for the most recent calendar year; and (E) any additional information the manufacturer chooses to provide related to drug pricing decisions;

(e) the savings attributable to the state, and to each county and the city of New York, due to the provisions of this article;

[(e)] (f) the aggregate amount of supplemental rebates received in the previous fiscal year and in the current fiscal year, to date; and such amounts are to be broken out by fiscal year and by month;

[(f)] (g) the education and outreach program established by section two hundred seventy-six of this [article] title.

§ 2. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.